Description

Immutep Limited is a biotechnology enterprise focused on the exploration and advancement of medicinal candidates. The company specializes in creating immunotherapeutic solutions for treating both cancerous conditions and autoimmune disorders. Its primary investigational drug is eftilagimod alpha (referred to as efti or IMP321), a recombinant protein currently in a Phase IIb clinical trial, being assessed as a chemoimmunotherapy combination for metastatic breast cancer. Furthermore, Immutep is progressing several other programs: TACTI-002, which is undergoing Phase II clinical evaluation for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003, in a Phase IIb clinical study for HNSCC; INSIGHT-004 and INSIGHT-003, both in Phase I clinical trials for solid tumors; and INSIGHT-005, a Phase I/IIa clinical trial for solid tumors. In addition to its oncology pipeline, the company's portfolio includes IMP761, an agonist targeting lymphocyte activation gene 3 for autoimmune diseases; IMP701, an antagonist antibody designed to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody aimed at eliminating T cells implicated in autoimmunity. Immutep Limited has established collaborative ventures with prominent organizations such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., the Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. Incorporated in 1987 and headquartered in Sydney, Australia, the company was formerly known as Prima BioMed Ltd, adopting the name Immutep Limited in November 2017.